Phase 2 clinical data of ARV-471 were published in November 2022[3], the CBR(CR+PR+ SD≥24w) of the primary endpoint for the ESR1 mutation subgroup was as high as 51%, and the PFS of the ESR1 mutation subgroup was 5.7 months. Safety studies showed that ARV-471 was well tolerated at...
the recommended Phase 3 dose (RP3D) of 200 mg (n=21), 400 mg (n=3) or 500 mg (n=20), plus 125 mg of palbociclib given orally once daily for 21 days, followed by seven days off treatment in 28-day cycles.
In a first-in-human phase 1/2 study, ARV-471 monotherapy was well tolerated and showed clinical activity in heavily pretreated patients with ER+/HER2- advanced breast cancer. The phase 3 monotherapy dose (200 mg once daily [QD]) was chosen due to comparable efficacy and favorable ...
参考文献:GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ERpositive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 ...
Vepdegestrant (ARV-471) (3, 10, and 30 mpk/day, orally) demonstrated significant antitumor activity in estradiol-dependent MCF7 xenografts, with a greater than 90% reduction in ER protein; even more significant tumor growth inhibition (131% TGI) was observed in the MCF7 xenograft model, wi...
原文出处:ARVINAS AND PFIZER ANNOUNCE UPDATED PHASE 1 DOSE ESCALATION DATA FOR ARV-471 TO BE PRESENTED IN SPOTLIGHT POSTER SESSION AT 2021 SAN ANTONIO BREAST CANCER SYMPOSIUM 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体...
[1]ArvinasAnnounces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC). Retrieved November 22, 2022 from网页链接 [2] Company Presentation, dated November 21, 2022. Retrieved Novembe...
原文出处:ARVINAS AND PFIZER ANNOUNCE UPDATED PHASE 1 DOSE ESCALATION DATA FOR ARV-471 TO BE PRESENTED IN SPOTLIGHT POSTER SESSION AT 2021 SAN ANTONIO BREAST CANCER SYMPOSIUM 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国患者了解国际新药动...
A Phase 2 dose expansion of ARV-471 is expected to begin in the first half of 2021. Arvinas also expects to initiate a Phase 1b cohort expansion of ARV-471 in combination with Ibrance® (palbociclib) in December 2020. This trial will evaluate the safety and tolerability of ARV-471 in ...
VERITAC-3: A randomized Phase 3 study, with a lead-in, of first-line vepdegestrant + palbociclib vs letrozole + palbociclib in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer Seth Wander TACTIVE-U Trial in Progress Poster Session...